Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma.
Adult
Aged
Aged, 80 and over
Aquaporin 4
/ genetics
Biomarkers, Tumor
/ genetics
Brain Neoplasms
/ genetics
Female
Glioblastoma
/ genetics
Humans
Isocitrate Dehydrogenase
/ genetics
Male
Middle Aged
Mutation
Neoplasm Recurrence, Local
/ diagnosis
Nestin
/ genetics
Nogo Proteins
/ genetics
Oligodendrocyte Transcription Factor 2
/ genetics
Prognosis
Promoter Regions, Genetic
Retrospective Studies
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
06
2019
accepted:
03
02
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
8
7
2020
Statut:
epublish
Résumé
Despite many years of research efforts and clinical trials the prognosis of patients diagnosed with glioblastoma remains very poor. The oligodendrocyte transcription factor 2 (Olig2) was identified as a marker for glioma stem cells, which are believed to be responsible for glioma recurrence and therapy resistance. In this retrospective analysis we assessed the prognostic value of oligodendroglial and glioma stem cell markers in 113 IDH-wildtype glioblastomas. Immunohistochemical staining for Olig2, NogoA, AQP4 and Nestin was performed in combination with sequencing of IDH1 and IDH2 as well as promotor methylation analysis of the MGMT gene. Even though differences in overall survival according to Olig2 expression were observed, univariate and multivariate survival analysis did not reveal a firm significant prognostic impact of Olig2, NogoA, AQP4 or Nestin expression. Additionally, no differences in the expression of these markers depending on clinical status, age or gender were found. The established independent prognostic factors age<65, Karnofsky Performance Status> = 70 and methylated MGMT gene promoter were significant in the multivariate analysis. In conclusion expression of oligodendroglial and glioma stem cell markers do not have an independent prognostic effect in IDH-wildtype glioblastoma.
Identifiants
pubmed: 32160197
doi: 10.1371/journal.pone.0229274
pii: PONE-D-19-17358
pmc: PMC7065747
doi:
Substances chimiques
AQP4 protein, human
0
Aquaporin 4
0
Biomarkers, Tumor
0
NES protein, human
0
Nestin
0
Nogo Proteins
0
OLIG2 protein, human
0
Oligodendrocyte Transcription Factor 2
0
IDH2 protein, human
EC 1.1.1.41
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229274Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cochrane Database Syst Rev. 2014 May 15;(5):CD007104
pubmed: 24833028
World Neurosurg. 2017 Oct;106:615-624
pubmed: 28729143
Acta Neuropathol Commun. 2017 Dec 15;5(1):98
pubmed: 29246238
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Oncotarget. 2017 May 9;8(19):32345-32355
pubmed: 28423683
J Neurooncol. 2015 Jan;121(2):359-64
pubmed: 25344883
Methods Mol Biol. 2015;1315:175-88
pubmed: 26103899
Cancer Res. 2018 Dec 15;78(24):6713-6716
pubmed: 30498082
J Neuropathol Exp Neurol. 2004 May;63(5):499-509
pubmed: 15198128
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3739-51
pubmed: 25120750
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Am J Surg Pathol. 2008 Oct;32(10):1444-53
pubmed: 18685489
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Neuro Oncol. 2007 Oct;9(4):424-9
pubmed: 17622647
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Biomarkers. 2011 Mar;16(2):136-43
pubmed: 21323603
Neuro Oncol. 2014 Jan;16(1):113-22
pubmed: 24285550
Neuron. 2007 Feb 15;53(4):503-17
pubmed: 17296553
Neuropathol Appl Neurobiol. 2007 Aug;33(4):431-9
pubmed: 17442061
J Clin Oncol. 2014 Mar 10;32(8):783-90
pubmed: 24516018
J Neurosci Res. 2007 May 1;85(6):1336-46
pubmed: 17335082
Neuro Oncol. 2013 Jan;15(1):91-6
pubmed: 23095230
Hum Pathol. 2012 Mar;43(3):374-80
pubmed: 21835431
Brain Tumor Pathol. 2012 Jul;29(3):160-7
pubmed: 22350668
Neuroscience. 2010 Jul 28;168(4):971-81
pubmed: 19761816
J Exp Clin Cancer Res. 2015 May 14;34:44
pubmed: 25967234
N Engl J Med. 2005 Aug 25;353(8):811-22
pubmed: 16120861
Cell Rep. 2016 Sep 13;16(11):2838-2845
pubmed: 27626655
Cell Cycle. 2017 Sep 17;16(18):1654-1660
pubmed: 28806136
Neuro Oncol. 2017 Aug 1;19(8):1068-1078
pubmed: 28339768
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuropathology. 2011 Oct;31(5):494-502
pubmed: 21269333
Front Oncol. 2017 Jun 16;7:120
pubmed: 28670569